Publications

Highlight publications

Other publications (53 papers)

Biomarkers

1. Stocker R, Pollicino C, Gay CA, Nestel P, Colquhoun D, Whiting M, Tonkin A, Sullivan D, Simes J. Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: A prospective case-control study from the LIPID study. Atherosclerosis 2006;187(1):198–204.

2. West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, Simes RJ, Pollicino C, Lubos E, Munzel TF, White HD, Tonkin AM, Bickel C, Tiret L, Blankenberg S, for the LIPID Study Investigators. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J 2008;29:923–931.

3. Soderberg S, Colquhoun D, Keech A, Yallop J, Barnes EH, Pollicino C, Simes J, Tonkin AM, Nestel P, for the LIPID Study Investigators. Leptin, but not adinopectin, is a predictor of recurrent cardiovascular events in men: Results from the LIPID study. Int J Obesity 2009;33:123–130.

4. Nestel PJ, Barnes EH, Tonkin AM, Simes J, Fournier M, White H, Colquhoun DM, Blankenberg S, Sullivan DR. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol 2013;33(12):2902–2908.

5. White HD, Simes J, Stewart RA, Blankenberg S, Barnes EH, Marschner IC, Thompson P, West M, Zeller T, Colquhoun DM, Nestel P, Keech AC, Sullivan DR, Hunt D, Tonkin A, LIPID Study Investigators. Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: Results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. J Am Heart Assoc 2013;2(5):e000360.

6. Funke-Kaiser A, Mann K, Colquhoun D, Zeller T, Hunt D, Simes J, Sullivan D, Sydow K, West M, White H, Blankenberg S, Tonkin AM, on behalf of the LIPID Study Investigators. Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. Int J Cardiol 2014;172(2):411–418.

7. White HD, Tonkin A, Simes J, Stewart R, Mann K, Thompson P, Colquhoun D, West M, Nestel P, Sullivan D, Keech AC, Hunt D, Blankenberg,S, for the LIPID study investigators. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: Results from the LIPID study. J Am Coll Cardiol 2014;63(4):345–54.

8. Tonkin AM, Blankenberg S, Kirby A, Zeller T, Colquhoun DM, Funke-Kaiser A, Hague W, Hunt D, Keech AC, Nestel P, Stewart R, Sullivan DR, Thompson PL, West M, White HD, Simes J. Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. Int J Cardiol 2015;201:499–507.

9. Driscoll A, Barnes EH, Blankenberg S, Colquhoun DM, Hunt D, Nestel PJ, Stewart RA, West MJ, White HD, Simes J, Tonkin A. Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model. Int J Cardiol 2017; 248: 361- 368.

10. Simes J, Robledo KP, White HD, Espinoza D, Stewart RA, Sullivan DR, Zeller T, Hague W, Nestel PJ, Glasziou PP, Keech AC, Elliott J, Blankenberg S, Tonkin AM. D-dimer predicts long-term cause- specific mortality, cardiovascular events and cancer in stable coronary heart disease patients: The LIPID study. Circulation 2018, in press.

Cholesterol Treatment Trialist's Collaboration (CTTC)

1. Cholesterol Trialists Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol 1995;75(16):1130–1134.

Design

1. LIPID Management Committee. Lowering cholesterol in patients with coronary heart disease: 4S results and the continuing rationale for LIPID. Med J Aust 162: 455–456, 1995.

2. The LIPID Study group. Design features and baseline characteristics of the LIPID (Long Term Intervention with Pravastatin in Ischaemic Disease) study: A randomised trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 1995;76:474– 479.

3. Tonkin A., for the LIPID Study Group. Management of the LIPID (Long Term Intervention with Pravastatin in Ischaemic Disease) Study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995;76S:107C–112C.

4. Tonkin A. Management of the LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease) Study after 4S. Circulation. 1995;76:109C–114C.

5. Glasziou PP, Simes RJ, Hall J, Donaldson C. Design of a cost-effectiveness study within a randomized trial: The LIPID trial for secondary prevention of IHD. Controlled Clin Trials 1997;18: 464–476.

Lipidomics

1. Alshehry ZH, Mundra PA, Barlow CK, Mellett NA, Wong G, McConville MJ, Simes J, Tonkin AM, Sullivan DR, Barnes EH, Nestel PJ, Kingwell BA, Marre M, Neal B, Poulter NR, Rodgers A, Williams B, Zoungas S, Hillis GS, Chalmers J, Woodward M, Meikle PJ. Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. Circulation. 2016;134:1637–1650.

Meta-analysis

1. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes E, Voysey M, Gray A, Collins R, Baigent C, on behalf of the Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta- analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590.

2. Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM, Jr., Ridker PM, Kastelein JJ. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: A meta-analysis. Circulation 2013;128(14):1504–1512.

Methods

1. Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, White H, Thompson P, Tonkin A, on behalf of the LIPID Study Investigators. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. J Am Coll Cardiol 2001;38:56–63.

2. Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart R, Hague W, Keech A, MacMahon S, White H, Shaw J, Tonkin A, on behalf of the LIPID Study Investigators. Relationship between lipid levels and clinical outcomes in the LIPID study. To what extent is the reduction in coronary events with pravastatin explained by lipid changes? Circulation 2002;105:1162–9.

3. Magliano D, Liew D, Pater H, Kirby A, Hunt D, Simes J, Sundararajan V, Tonkin A. Accuracy of the Australian National Death Index: Comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. ANZ J Public Health 2003; 27: 649–653.

4. Cui J, Forbes A, Kirby A, Marschner I, Simes J, West M, Tonkin A. Parametric conditional frailty models for recurrent cardiovascular events in the LIPID study. Clinical Trials 2008;5:565–574.

5. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A; LIPID Study Investigators. Monitoring cholesterol levels: Measurement error or true change? Ann Intern Med 2008;148(9):656–661.

6. Cui J, Forbes A, Kirby A, Simes J, Tonkin A. Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: The LIPID study. Eur J Cardiovasc Prevent Rehab 2009;16(6): 60–668.

7. Cui J, Forbes A, Kirby A, Marschner I, Simes J, Hunt D, West M, Tonkin A. Semi-parametric risk prediction models for recurrent cardiovascular events in the lipid study. BMC Med Res Methodol 2010;10(1):27.

8. Bell K, Kirby A, Hayen A, Irwig L, Glasziou P. Monitoring adherence to drug treatment by using change in cholesterol concentration: Secondary analysis of trial data. BMJ (Clinical Research Ed). 2011;342:d12.

9. Glasziou PP, Irwig L, Kirby AC, Tonkin AM, Simes RJ. Which lipid measurement should we monitor? An analysis of the LIPID study. BMJ Open 2014;4(2):e003512.

Secondary results

1. Stewart RA, Sharples KJ, North FM, Menkes DB, Baker J, Simes J., for the LIPID Study Investigators. Long-term assessment of psychological well-being in a randomised placebo- controlled trial of cholesterol reduction with pravastatin. Arch Int Med 2000;160:3144–3152.

2. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G, Tonkin A, for the LIPID investigators. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients. Ann Intern Med 2001;134:931–940.

3. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N, on behalf of the LIPID Study Investigators. Effect of pravastatin on frequency of fracture in the lipid study: Secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet. 2001;357(9255):509–512.

4. West MJ, White HD, Simes RJ, Kirby A, Watson JD, Anderson NE, Hankey GJ, Wonders S, Hunt D, Tonkin AM. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. J Hypertension 2002;20:2513–2517.

5. Stewart R, North F, West T, Sharples K, Simes RJ, Colquhoun D, White HD, Tonkin AM, for the LIPID Study Investigators. Depression and cardiovascular morbidity and mortality: Cause or consequence? Eur Heart J 2003;24:2027–2037.

6. Stewart RAH, White HD, Kirby AC, Heritier SR, Simes RJ, Nestel PJ, West MJ, Colquhoun DM, Tonkin AM, for the Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Investigators. The white blood cell count predicts the likelihood of a reduction in coronary heart disease mortality with pravastatin treatment. Circulation 2005; 111: 1756–1762.

7. Stewart RA, North FM, Sharples KJ, Simes RJ, Tonkin AM, White HD; for the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Investigators. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: Findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. NZ Med J 2008; 121:11–23.

8. Stewart RAH, Colquhoun DM, Marschner SL, Kirby AC, Simes J, Nestel PJ, Glozier N, O'Neil A, Oldenburg B, White HD, Tonkin AM. Persistent psychological distress and mortality in patients with stable coronary artery disease. Heart 2017;103:1860–1866.

Subgroup

1. Tonkin AM, Colquhoun D, Emberson J, Hague W, Keech A, Lane G, MacMahon S, Shaw J, Simes RJ, Thompson PL, White HD, Hunt D, for the LIPID Study Group. Effects of pravastatin in 3260 patients with unstable angina: Results from the LIPID study. Lancet 2000; 355: 1871–1875.

2. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G, Tonkin A, for the LIPID Investigators. Benefits of pravastatin on cardiovascular events in older patients with coronary heart disease. Cardiol Rev 2002;19(6): 34.

3. Hague W, Forder P, Simes J, Hunt D, Tonkin A, on behalf of the LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: Results from the LIPID study. Am Heart J 2003;145:643–651.

4. Keech AC, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A, for the LIPID study group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: Results from the LIPID trial. Diabetes Care 2003;26:2713–2721.

5. Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A, for the LIPID study investigators. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: Results from the LIPID study. Eur Heart J 2004;25:771–777.

Substudy

1. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, White H. Effects of lowering average or below average cholesterol levels on the progression of atherosclerosis. Results of the LIPID atherosclerosis substudy. Circulation 1998;97:1784–1790.

2. Glasziou P, Eckermann S, Mulray S, Simes RJ, Martin A, Hall J, Caleo J, Hall JP, White HD, Tonkin AM. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: Is it cost-effective? Med J Aust 2002;177: 428–434.

3. Nestel PJ, Baghurst K, Colquhoun DM, Simes RJ, Mehalski K, White HD, Tonkin AM, Kirby A, Pollicino C, for the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Investigators. Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: Analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial. Am J Clin Nutr 2005;81:1322–1329.

4. Tonkin AM, Eckermann S, White H, Friedlander D, Glasziou P, Magnus P, Kirby A, Mulray S, Denton M, Sallaberger M, Hunt D, Simes J, on behalf of the LIPID Study Investigators. Cost- effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65–74 years compared with younger patients: Results from the LIPID study. Am Heart J 2006;151(6):1305–1312.

Triple P

1. Pravastatin Pooling Project Investigators. Design, rationale and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project: A combined analysis of three large-scale randomized trials: Long term intervention with pravastatin in ischemic disease (LIPID), cholesterol and recurrent events (CARE), and west of Scotland coronary prevention study (WOSCOPS). Am J Cardiol 1995;76:899–905.

2. Sacks FT, Tonkin AM; Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project. Circulation 2000;102(16):1893–1900.

3. Sacks F, Tonkin A, Craven T, Pfeffer M, Shepherd J, Keech A, Furberg C, Braunwald E. Coronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002;105(12):1424–1428.

4. Tonelli MI, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110(12):1557–1563.

5. Tonelli MI, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112(2):171–178.

6. Tonelli MK, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005;16(12):3748–3754.

7. Pfeffer M, Keech A, Sacks F, Cobbe S, Tonkin A, Byington R, Davis B, Friedman C, Braunwald E. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105(20):2341–2346.

8. Simes RJ, Furburg CD, Braunwald E, Davis BR, Ford I, Tonkin A, Shepherd J, for the Prospective Pravastatin Pooling Project. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels: The Prospective Pravastatin Pooling Project. Eur Heart J 2002;23(3):207–215.